The FEAST trial of fluid bolus in African children with severe infection – Authors' reply

What I said was: "The main message--fluid boluses are dangerous in children with malaria, and in other common febrile illnesses in which ADH secretion is likely to be high--is important to disseminate clearly" and "This trial does not inform about the management of other shock conditions: dengue shock syndrome in Asia, or hypovolaemic shock from diarrhoea and vomiting. In the future, when a trial steering committee and DSMB is to consider a major protocol amendment (such as doubling the dose of a drug or intervention), it would be prudent to have up-to-date data on whether the primary outcome differs significantly between the study groups before enacting such a change--especially if the outcome was mortality.